Pfizer monitors growth drug in korean children for six years
NCT ID NCT05509894
Summary
This study is monitoring the safety and effectiveness of Ngenla, a growth hormone treatment, in children with growth hormone deficiency in Korea. It will follow 565 children and adolescents for six years during their regular treatment. The main goal is to track any side effects while also measuring how well the treatment helps children grow taller.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.